Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

21. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. (PubMed)

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. Methods In this double-blind, placebo-controlled, phase 3 trial (...) , we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival. Results After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median

Full Text available with Trip Pro

2017 NEJM

22. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial

Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial 28450312 2017 04 28 2017 06 01 1468-2060 2017 Apr 27 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid (...) Arthritis trial. annrheumdis-2016-210647 10.1136/annrheumdis-2016-210647 In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD

2017 EvidenceUpdates

23. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. (PubMed)

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. BACKGROUND: High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could (...) participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24

2017 Lancet

24. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia

Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia 27471201 2016 07 29 2016 10 03 1399-3003 48 4 2016 Oct The European respiratory journal Eur. Respir. J. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. 1150-1159 10.1183/13993003.00474-2016 In a double-blind, randomised, placebo-controlled trial of hospitalised patients with community-acquired pneumonia (CAP), we demonstrated shorter time to clinical stability (TTCS (...) ) with adjunct corticosteroid therapy compared with placebo.We did a pre-planned, exploratory analysis of any association between microbiological diagnosis, antibiotic treatment and procalcitonin level and effect of prednisone on TTCS, mortality, and CAP complications (n=726 participants, enrolled between December 2009 and May 2014). Multiplex viral real time PCR was systematically performed in nasopharyngeal swabs beginning November 2011 (n=489). Other investigations and treatments were at the discretion

Full Text available with Trip Pro

2016 EvidenceUpdates

25. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy (PubMed)

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy 27566742 2016 08 27 2017 05 12 2017 05 12 1526-632X 87 20 2016 Nov 15 Neurology Neurology Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. 2123-2131 To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD). This phase III, double-blind, randomized, placebo-controlled, multicenter study evaluated (...) Justine (M.V.), Montreal, Canada; and Marathon Pharmaceuticals, LLC (J.S.D., J.M.M.), Northbrook, IL. eng Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial 2016 08 26 United States Neurology 0401060 0028-3878 0 Anti-Inflammatory Agents 0 Pregnenediones KR5YZ6AE4B deflazacort VB0R961HZT Prednisone AIM IM Lancet Neurol. 2010 Feb;9(2):177-89 19945914 Neuromuscul Disord. 1991;1(4):261-6 1822804 J Clin Neuromuscul Dis. 2001 Jun;2(4):179-83 19078632

Full Text available with Trip Pro

2016 EvidenceUpdates

26. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 (PubMed)

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 26888258 2016 04 29 2017 02 03 1528-0020 127 17 2016 Apr 28 Blood Blood Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. 2101-12 10.1182/blood-2015-09-670729 Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic (...) potency, leading to fewer relapses and improved survival. After a 7-day prednisone prephase, 3720 patients enrolled on trial Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL 2000 were randomly selected to receive either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus tapering in induction. The 5-year cumulative incidence of relapse (± standard error) was 10.8 ± 0.7% in the dexamethasone and 15.6 ± 0.8

Full Text available with Trip Pro

2016 EvidenceUpdates

27. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma (PubMed)

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma 26802176 2016 03 04 2016 07 27 2016 03 04 1528-0020 127 9 2016 Mar 03 Blood Blood Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. 1109-16 10.1182/blood-2015-11-679415 The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma (...) who are ineligible for stem cell transplantation. Long-term treatment with thalidomide is hampered by neurotoxicity. Melphalan, prednisone, and lenalidomide, followed by lenalidomide maintenance therapy, showed promising results without severe neuropathy emerging. We randomly assigned 668 patients between nine 4-week cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide

Full Text available with Trip Pro

2016 EvidenceUpdates

28. Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away?

Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary (...) care research. www.acfp.ca May 9, 2016 Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Clinical Question: Are 1-2 doses of dexamethasone as effective as the standard five day prednisone regimen for treatment of pediatric asthma exacerbations? Bottom-line: Treatment of pediatric asthma exacerbations with short-course dexamethasone (0.6 mg/kg x 1-2 doses) is a safe and effective alternative to traditional five day courses of prednisone. For every ~20 children

2016 Tools for Practice

29. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL (PubMed)

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL 26232170 2015 10 16 2016 01 14 2017 02 20 1528-0020 126 16 2015 Oct 15 Blood Blood Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. 1893-901 10.1182/blood-2015-03-632430 This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus (...) cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method). In total, 164 patients were randomized 1:1 to receive six 21-day cycles of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), and doxorubicin 50 mg/m(2), all IV day 1, prednisone 100 mg/m(2) orally days 1-5, plus either bortezomib 1.3 mg/m(2) IV days 1, 4, 8, 11 (rituximab

Full Text available with Trip Pro

2016 EvidenceUpdates

30. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. (PubMed)

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. BACKGROUND: Clinical trials yielded conflicting data about the benefit of adding systemic corticosteroids for treatment of community-acquired pneumonia. We assessed whether short-term corticosteroid treatment reduces time to clinical stability in patients admitted to hospital for community-acquired pneumonia. METHODS: In this double-blind, multicentre (...) , randomised, placebo-controlled trial, we recruited patients aged 18 years or older with community-acquired pneumonia from seven tertiary care hospitals in Switzerland within 24 h of presentation. Patients were randomly assigned (1:1 ratio) to receive either prednisone 50 mg daily for 7 days or placebo. The computer-generated randomisation was done with variable block sizes of four to six and stratified by study centre. The primary endpoint was time to clinical stability defined as time (days) until

2015 Lancet

31. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

2015 Annals of Emergency Medicine Systematic Review Snapshots

32. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial (PubMed)

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial 24075621 2013 11 01 2013 12 27 2015 11 19 1474-5488 14 12 2013 Nov The Lancet. Oncology Lancet Oncol. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase (...) 3 trial. 1193-9 10.1016/S1470-2045(13)70424-8 S1470-2045(13)70424-8 Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone. We describe analyses of data for patient-reported pain and functional status in a preplanned interim analysis of a phase 3 trial. Between April 28, 2009, and June 23, 2010, patients

2014 EvidenceUpdates

33. Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer (PubMed)

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer 24323035 2014 01 09 2014 03 03 2016 11 25 1527-7755 32 2 2014 Jan 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant (...) prostate cancer. 76-82 10.1200/JCO.2012.48.5268 We evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC). Men with progressive mCRPC after docetaxel-based chemotherapy were randomly assigned 2:1 to receive sunitinib 37.5 mg/d continuously or placebo. Patients also received oral prednisone 5 mg twice daily. The primary end point was overall survival (OS); secondary end points included progression-free survival

2014 EvidenceUpdates

34. Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department

Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Article Text

2014 Evidence-Based Medicine (Requires free registration)

35. Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re (PubMed)

Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re 23492671 2013 06 17 2014 01 23 2015 11 19 1522-9645 34 23 2013 Jun European heart journal Eur. Heart J. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention (...) of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). 1740-8 10.1093/eurheartj/eht079 To analyse the clinical outcome at 4 years in patients with coronary artery disease treated with bare metal stents (BMS) vs. BMS and oral prednisone, or drug-eluting stents (DES), all assuming similar adjunctive medical treatment. Five Italian hospitals enrolled 375 non-diabetic, ischaemic patients without contraindications to dual anti

Full Text available with Trip Pro

2013 EvidenceUpdates

36. Azathioprine with prednisone for polymyositis. A controlled, clinical trial.

Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Azathioprine with prednisone for ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1980 ) Volume: 92 , Issue: 3 , Pages: 365-369 PubMed: Available from or Find this paper at: Abstract A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis (...) . Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 months. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly

2013 Annals of Internal Medicine

37. The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review

The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review "The Efficacy of Prednisone Versus Antivirals in the Complete Recovery " by Robin Tyner < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Bell’s palsy is an idiopathic condition, caused by inflammatory injury to the facial nerve, resulting (...) viral etiology. Does the use of antivirals alone or in conjunction with steroids substantially increase the overall recovery in patients with Bell’s palsy? Methods: An exhaustive search was conducted using Medline-OVID, CINAHL-EBSCOhost, EBMR Multifile, and Web of Science using the keywords: Bell’s palsy, antiviral agents and prednisone or prednisolone. The NIH clinical trials site revealed no on-going or registered trials comparing the treatment of steroids and antivirals in patients with Bell’s

2013 Pacific University EBM Capstone Project

38. Bortezomib (Velcade) - in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma

Bortezomib (Velcade) - in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma

2012 Scottish Medicines Consortium

39. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri (PubMed)

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri 23142059 2012 11 27 2013 02 04 2016 11 25 1474-5488 13 12 2012 Dec The Lancet. Oncology Lancet Oncol. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients (...) collected as part of the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus prednisone in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. The COU-AA-301 trial enrolled patients with metastatic castration-resistant prostate cancer in whom one or two lines of chemotherapy (one docetaxel based) had been unsuccessful and who had Eastern Cooperative Oncology Group performance statuses of 2 or less. Pain intensity

2012 EvidenceUpdates

40. Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC)

Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC)

2012 Scottish Medicines Consortium